OHDSI Home | Forums | Wiki | Github

Welcome to OHDSI! - Please introduce yourself

General
#163

Hello everyone,

I am Erwin Böttinger, CEO of the Berlin Institute of Health (BIH) and PI of a research
consortium (“Health Data for Care and Research” – HD4CR) that aims to efficiently
interlink health care, biomedical and research data to improve patient care and
medical research in the long run. The ultimate goal is an interoperable and
interlinked digital health and research basis enabling value-based,
personalized healthcare.

As to OHDSI, my main interest is in the (professional) exchange of information and ideas
in the OHDSI-community. I am excited to see, how our consortium can contribute to
OHDSI and vice versa, how our undertakings can contribute to the goals of the OHDSI
program.

What kind of person is the CDM's user?
#164

Hi, I’m Renee Taylor, a consultant at the California Department of Health Care Services, now working on an OMOP CDM mapping from T-MSIS. Has anyone else done this, just in case :)?

My background is enterprise data modelling and enterprise architecture, including Medicaid Information Technology Architecture work (the CMS framework).
Glad to join you!

#165

Hi, Jim! So glad to discover you in this community. I’d love to hear more about your population health study and how you’re using (or if you’re using) OMOP. P.S. If you’re heading to Orlando for SGF in April, we should connect. But no scary rides this time. :wink:

#166

I am John Evenden, the Director of Science for Cambridge Cognition. I am a psychologist by training, and have experience with designing computerised neuropsychological tests. I heard a talk by Patrick Ryan at the recent ISCTM meeting, and it struck me that the databases accessible through OHDSI might contain the information that would help map out the prevalence of clinically-relevant cognitive problems reported by patients themselves, and the way they change during the course of disease and in response to treatments. For example, our experience suggests that the wrong mix of patients is being recruited to trials of pro-cognitive drugs in disease like schizophrenia, depression and ADHD, which may contribute to the high failure rate of clinical trials in this area. We are also often asked to provide support for studies on cognition in non-CNS diseases like cancer or cardiovascular disease. A better understanding of the problems that patients complain of in their everyday life could help focus studies on appropriate endpoints for laboratory-based assessments.
.
I have no background in this type of work, and don’t really understand the terminology or the tools, so I have focussed my time so far on reading the e-mail exchanges and listening to presentations and discussions on the weekly forums. I am also intending to go through the training videos. I already saw that there may be people in the network who are interested in mental health or neurological disorders. It would be great to collaborate to identify specific questions which could be addressed by the techniques the OHDSI team has available.

#167

Who’s Jim, @rosebraun? :smile:

#168

Hi, John,
Me and my team are currently working on OHDSI-vocabularies (http://athena.ohdsi.org/) and CDM data conversion at ODYSSEUS DATA SERVICES.
I’m a psychiatrist, so I’m excited to use my both psychiatry and OHDSI data knowledge.
Thus ping me if you need some help.

#169

Hi, Dmytry

I am just a beginner at this, trying to understand the process and the terminology. I certainly don’t have the skills or experience myself to get involved with the databases myself anytime soon. At this time I mainly trying to imagine how to best formulate a question that would be interesting and practical for someone like yourself to get interested in.

So… my employer sells software to do cognitive tests. We have a lot of customers in the academic research community who do laboratory based measures of cognition, and sometimes also interview the subjects about their cognitive capabilities in everyday life as part of that office-based assessment. However, there has always been a question about how relevant this type of research is to patients performance in everyday life. As with investigating many psychological issues, the problem is that any attempt to measure performance in everyday life inevitably involves interfering in some way, which can change the very behavior you are trying to measure.

In listening to Patrick Ryan it occurred to me that perhaps it would be possible to get a different type of estimate of how important cognitive problems are to patients with mental health or neurological problems from analysing the type of issues that they discuss with their doctors. Obviously there is also an interest in this community for looking at the effects of interventions, and there are certainly “hot topics” of that nature, such as do antidepressants improve cognition in people with MDD.

The kind of fundamental questions that are going in my mind, are things like:
What kind of words do patients use to discuss cognitive problems with their doctors? And are these found in the various databases in OHDSI? How do we find out?
Can we use Alzheimer’s disease as a “gold standard”? After all people diagnosed with Alzheimer’s disease should have complained to their doctors about memory difficulties. Or ADHD? The medical records of patients with ADHD should contain references to attention problems, but perhaps also other terms like restlessness or “easily distracted” or “can’t focus” which are not exactly the same thing but represent the type of information which I have seen in doctors summaries of patients problems.

Does this sound interesting to you?

John

#170

Hi, This is Jin Zhou. I am an assistant prof of biostatistics at the university of Arizona. I am interested in how to identify subgroups of individuals whos treatment effects can be optimized, or treatment heterogeneity effects using observational data. Currently I am interested in VA’s records datasets, but great to know this recourse, very much set the platform for a newcomer.

#171

Hello. My name is Neil Martinez. I am a Communications and Management Consultant facing the Life Sciences Industry. I have worked with industry professionals across the entire life cycle of development and commercialization for the past 20+ years. I am developing a common metadata model / methodology for life sciences companies and organizations that are making the leap from pre-commercial to commercialization.

A friend of mine that I knew from Bristol-Myers Squibb suggested I join this group. I managed a project he had to develop a web-based interface to patient claim data using commercially available SAS data sets. Since then I’ve managed the aggregation and analysis of US-based customer data for several clients driven by both CIA agreements and regulatory mandates.

I’ve also managed projects as diverse as migrating study plan data from/to Enterprise Project Management platforms, implementing programmatic controls to ensure FCPA compliance in purchasing systems, streamlining the procurement process (for professional services) from a business process perspective, and the redesign of Data Management and Analytics platforms across a $2.2B therapeutic area for a global pharma.

I live in Southern New Jersey, USA. I flunked out of Art School after a half year. I do not have a formal degree from anywhere but I have professional certifications from Microsoft (Dynamics CRM) and the Project Management Institute (PMP).

#172

Hi, I am Peter Heuschmann and I am chair of the Institute for Clinical Epidemiology and Biometry (ICE-B) at the medical faculty of the University of Würzburg.
The research activities of our institute are structured into three main research areas: clinical research; clinical epidemiology and health services research, setting the focus on actionable conditions. Using a wide variety of methods and data we are always interested in learning more about new applications and tools. So I welcome the opportunity to get familiar with tools provided by ODHSI.

#173

Hello,

My name is Jay Chatfield, and I am tenured Life Science Professional. During my 15-year tenure at Merck, I was a project manager in strategic alliances/business development and a science/strategy lead for a gram (+) antibiotic portfolio. I also had the privilege to collaborate with Premier, Inc., which is the largest healthcare alliance organization in the U.S. Working with Premier and, their alliance of health systems; I helped design biosimilar and vaccine population health initiatives and leveraged real-world data that identified unmet needs in recurrent C. difficile infection.

Currently, I am with Orexigen Therapeutics Inc., where I work on obesity population health initiatives and market access strategies for self-insured employers as well as integrated payer – provider health systems. We must understand specific needs of high-risk populations to identify cost-effective interventions, and I believe my experience in population health can support many needs throughout the OHDSI community. When not working I jump on the trampoline with my rambunctious seven-year-old twin boys. Truthfully, they jump on me!

#174

Hi I’m Heather Whitaker, stats lecturer at The Open University in the UK, and busy mum of two.

My work is in statistical methods for epidemiology, especially SCCS and self-controlled methods in general. I am especially interested in some of the methodological work that has been produced by ODHSI and would like to keep up to date with this part of your work, better understand your challenges and contribute if I can.

#175

Hi all, My name is Adib Zaman, a research scientist at the Regenstrief Center for Healthcare Engineering located at Purdue University, Indiana.
My interest is in the domain of integration of medical device data with EHRs, share-ability of research works (coding), and causal inference from observational data. I am working on multiple grant proposals in these domain with intensive care unit data. I am exploring opportunities to work for grant proposals with OHDSI as well as learning more about OHDSI.

Adib

#176

Hi All,

My Name is Nitish Kumar Jha working in JSS medical research India.
I am going to start ETL for a registry study for the first time.It would be really helpful if anyone can let me know how to start in this regard:
I have the raw datasets in SAS format and The CRF of the project ,
what else I need to start the process?
do I need some specific software like White Rabbit etc. ?

regards
Nitish Kumar Jha

ETL for a SAS-based registry study
#177

@nitishkjha:

Welcome to the family.

This is an introduction stream, so I took the liberty to try an answer to your question here.

#178

Hello All, my name is Colleen Erickson, working with the Evalytica team, and I am interested in keeping up-to-date with OHDSI tools and standards.

#179

Hello! I’m Adam Wright, a senior scientist at Brigham and Women’s Hospital (part of Partners HealthCare) in Boston and an associate professor at Harvard. I’m interested in clinical decision support and clinical data mining, especially related to detecting adverse drug events (ADEs). I’m interested in looking at ways we can detect both known ADEs (i.e. from the literature of experts) more accurately and also find previously-unknown patterns of ADEs. My research website is here: http://wrightlab.bwh.harvard.edu/. I’d love to collaborate with other OHDSI members on these kinds of studies, and also look at how we could map some of the data we have to the common data model.

#180

Hello. I am Michael Seungcheol Kang, an orthopaedic surgeon working in Asan Medical Center, Seoul, Korea. My subspecialty is pediatric orthopaedic surgery. I’m interested in various medical fields such as injury, sports, deformity, pain… And I and my research colleagues in our institute are currently converting the recent-5-years clinical data into the format of OMOP CDM version 5. I really want to collaborate with many other members.

#181

Hello Group,

I am Amit Kumar, a CDISC SDTM Mapping Specialist working in Cytel India. Right now I have got one OMOP CDM Project for ETL creation for an observational study.

We are generating DRUG_EXPOSURE Table in which I have some doubts ,

  1. Should we collect all Drug Exposure data captured in raw data like Prior Medication, Study Medication ??
  2. Most of Medication History data does not captures date what can we about that.?
    3.What are refill? can we keep them blank?
  3. How to generate drug_exposure_id ?

Kindly guide me as our team is doing it for first time.

DRUG_EXPOSURE conventions
#182

@Amit:

Welcome to the family!

This is an introduction stream, so it’s probably not a good idea to discuss detail here. I’ll start a new posting here.

But in general: For a full-fledged ETL conversion, you will run into a lot of questions like the ones above. It’s probably not a good idea to do this in the Forum piece-meal. What you need is a one-day work session. There are a few folks who will gladly do this for you, but you may have to compensate them a little bit.

t